RxDoctor Payments Data

David Meyer, MD

Internal Medicine · Lincolnton, NCNPI 1225353477

Payments from drug & device makers

$237in general payments, 2019–2025

Across 8 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$102
  • Dexcom, Inc.$44
  • Novartis$38
  • EMD Serono, Inc.$21
  • Novo Nordisk$17
  • GSK$14

What the payments were for

  • Food & beverage$237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$102
Dexcom, Inc.2$44
Novartis2$38
EMD Serono, Inc.1$21
Novo Nordisk1$17
GSK1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$237 in reported general payments places this provider in the 55th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$116,133
Medicare patients
152
Services billed
1,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin145$124,451
OzempicSemaglutide119$119,329
EliquisApixaban94$74,362
ArexvyRsvpref3 Antigen/As01e/Pf107$33,438
MounjaroTirzepatide28$29,616
FarxigaDapagliflozin Propanediol33$25,974
Victoza 3-PakLiraglutide15$15,497
TrulicityDulaglutide16$15,136
XareltoRivaroxaban13$12,682
ShingrixVaricella-Zoster Ge/As01b/Pf53$11,946
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf116$8,150
Arnuity ElliptaFluticasone Furoate13$4,879
Levemir FlexpenInsulin Detemir18$3,905
Omeprazole246$3,364
Pravastatin Sodium273$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$119,329119 claims
PfizerEliquis$102$74,36294 claims
GSKArexvy, Shingrix, Arnuity Ellipta$14$50,262173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Lincolnton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →